The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).
Juan W. Valle
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca; Lilly
Research Funding - AstraZeneca
Harpreet Wasan
Honoraria - Lilly
Other Remuneration - Lilly
Mark Jitlal
No relevant relationships to disclose
Alison Catherine Backen
No relevant relationships to disclose
Daniel H. Palmer
No relevant relationships to disclose
Marian Duggan
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
David Alan Anthoney
No relevant relationships to disclose
Philippa Corrie
No relevant relationships to disclose
Srinivasan Madhusudan
No relevant relationships to disclose
Anthony Maraveyas
No relevant relationships to disclose
Paul J. Ross
No relevant relationships to disclose
Justin S. Waters
No relevant relationships to disclose
William P. Steward
No relevant relationships to disclose
Charlotte Rees
No relevant relationships to disclose
Sandy Beare
Research Funding - AstraZeneca
Caroline Dive
No relevant relationships to disclose
John A. Bridgewater
Consultant or Advisory Role - AstraZeneca; Merck; Roche; Sanofi